Femring
NDC Package 72495-302-10
Package Information
Femring (estradiol acetate) rings is femring is contraindicated in women with any of the following conditions:•Undiagnosed abnormal genital bleeding•Known, suspected, or history of breast cancer•Known or suspected estrogen-dependent neoplasia•Active DVT, PE, or history of these conditions•Active arterial thromboembolic disease (for example, stroke and MI), or a history of these conditions•Known anaphylactic reaction or angioedema to Femring•Known liver impairment or disease•Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders•Known or suspected pregnancy. This formulation utilizes a ring delivery system. Marketed by Millicent Us, Inc., this product is identified by NDC 72495-302 and is authorized under FDA application NDA021367.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 72495 - Millicent Us, Inc.
- 72495-302 - Femring
- 72495-302-10 - 1 POUCH in 1 CARTON / 90 d in 1 POUCH
- 72495-302 - Femring
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 72495-302-10 identifies a specific commercial package of 1 pouch in 1 carton / 90 d in 1 pouch of Femring, a human prescription drug labeled by Millicent Us, Inc.. This ring is formulated for vaginal use and contains estradiol acetate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Millicent Us, Inc. on August 01, 2026. The current certification is valid through December 31, 2027.
How is this Millicent Us, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 72495030210. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.